Single Assay Enables Simultaneous Newborn Screening for Three Severe Genetic Disorders

Spinal muscular atrophy, severe combined immunodeficiency, and sickle cell disease can lead to rapid disability, severe infections, or early mortality if not recognized promptly, highlighting the need for consolidated assays that fit routine screening workflows. Addressing this need, a newly launched CE-marked assay now screens for all three conditions simultaneously.

TIB MOLBIOL, a Roche Diagnostics subsidiary, has introduced the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic assay for newborn screening in countries that accept the CE mark. The kit simultaneously screens for spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID), and sickle cell disease (SCD) in a single assay designed for routine laboratory use. It is intended for private and academic hospital laboratories seeking standardized implementation without extensive in-house method development.

The assay runs on established LightCycler systems, enabling laboratories already using the platform to incorporate the new screen with minimal disruption. It is described as a first‑tier test that can immediately trigger confirmatory diagnostics and treatment planning when results indicate risk. The kit expands Roche’s early diagnostics portfolio while emphasizing integration into existing laboratory workflows.

Early detection is highlighted as central to clinical benefit. Identifying SMA at birth allows clinicians to initiate targeted therapies that may prevent severe nerve damage, permanent disability, and missed developmental milestones. For SCD, prompt recognition supports interventions such as preventive penicillin and specialized immunizations that can reduce infant mortality. In SCID, diagnosing the condition before infections occur enables potentially lifesaving measures, including bone marrow transplantation.

“When a baby is born with a condition like SMA or SCID, every single day counts. Catching these diseases before symptoms appear isn't just about early diagnosis; it's the difference between a child thriving or facing severe, lifelong disability. By expanding our compliant newborn screening tools across Europe, we are helping laboratories transition to high-precision solutions that ensure no critical diagnosis is delayed,” said Marcus Droege, CEO of TIB MOLBIOL.